Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital

Pediatric toxic epidermal necrolysis treated successfully with infliximab

Research output: Contribution to journalJournal articleResearchpeer-review


  1. The successful use of extracorporeal photopheresis in a 12-year-old patient with refractory epidermolysis bullosa acquisita

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Dupilumab for prurigo nodularis: Case series and review of the literature

    Research output: Contribution to journalReviewResearchpeer-review

  2. Scabies

    Research output: Contribution to journalJournal articleCommunication

  3. Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis

    Research output: Contribution to journalLetterResearchpeer-review

  4. Behandling og forebyggelse af fnat

    Research output: Contribution to journalJournal articleCommissioned

  5. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Lana Chafranska
  • Ditte Marie Saunte
  • Nille Behrendt
  • Ulrikka Nygaard
  • Ryan J Christensen
  • Carsten Sand
  • Gregor B Jemec
View graph of relations

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults. We present a case of a 7-year-old boy with infection-associated TEN, diagnosed by typical clinical and histopathological features, most likely caused by Mycoplasma pneumoniae. Treatment with a single dose of infliximab 5 mg/kg intravenously on day 5 after the onset of symptoms was followed by cessation of all blister formation over 3 days and complete resolution within a week. Sequelae were mild, consisting of postinflammatory hyperpigmentation and dry eyes.

Original languageEnglish
JournalPediatric Dermatology
Issue number3
Pages (from-to)342-345
Number of pages4
Publication statusPublished - May 2019

    Research areas

  • Child, Dermatologic Agents/therapeutic use, Humans, Infliximab/therapeutic use, Male, Mycoplasma pneumoniae/isolation & purification, Stevens-Johnson Syndrome/drug therapy

ID: 58959023